Sol-Gel SLGL Stock
Sol-Gel Price Chart
Sol-Gel SLGL Financial and Trading Overview
| Sol-Gel stock price | 0.47 USD |
| Previous Close | 3.01 USD |
| Open | 3.1 USD |
| Bid | 1.34 USD x 4000 |
| Ask | 3.32 USD x 2900 |
| Day's Range | 3.1 - 3.36 USD |
| 52 Week Range | 3 - 6.89 USD |
| Volume | 16.92K USD |
| Avg. Volume | 18.8K USD |
| Market Cap | 75.4M USD |
| Beta (5Y Monthly) | 1.277464 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.34 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.5 USD |
SLGL Valuation Measures
| Enterprise Value | 44.19M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.344262 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 16.257475 |
| Price/Book (mrq) | 1.9019836 |
| Enterprise Value/Revenue | 9.528 |
| Enterprise Value/EBITDA | -2.165 |
Trading Information
Sol-Gel Stock Price History
| Beta (5Y Monthly) | 1.277464 |
| 52-Week Change | -32.78% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.89 USD |
| 52 Week Low | 3 USD |
| 50-Day Moving Average | 3.55 USD |
| 200-Day Moving Average | 4.45 USD |
SLGL Share Statistics
| Avg. Volume (3 month) | 18.8K USD |
| Avg. Daily Volume (10-Days) | 19.46K USD |
| Shares Outstanding | 23.13M |
| Float | 8.4M |
| Short Ratio | 2.59 |
| % Held by Insiders | 55.08% |
| % Held by Institutions | 22.24% |
| Shares Short | 43.83K |
| Short % of Float | 0.77% |
| Short % of Shares Outstanding | 0.19% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -450.60% |
| Gross Margin | -288.65% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -24.85% |
| Return on Equity (ttm) | -41.59% |
Income Statement
| Revenue (ttm) | 4.64M USD |
| Revenue Per Share (ttm) | 0.2 USD |
| Quarterly Revenue Growth (yoy) | 25166.70% |
| Gross Profit (ttm) | -8799000 USD |
| EBITDA | -20416500 USD |
| Net Income Avi to Common (ttm) | -19589000 USD |
| Diluted EPS (ttm) | -0.83 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 33.75M USD |
| Total Cash Per Share (mrq) | 1.31 USD |
| Total Debt (mrq) | 574K USD |
| Total Debt/Equity (mrq) | 1.3 USD |
| Current Ratio (mrq) | 10.369 |
| Book Value Per Share (mrq) | 1.714 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Sol-Gel
| Country | United States |
| State | N/A |
| City | Ness Ziona |
| Address | 7 Golda Meir Street |
| ZIP | 7403650 |
| Phone | 972 8 931 3433 |
| Website | https://www.sol-gel.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 55 |
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610, a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Q&A For Sol-Gel Stock
What is a current SLGL stock price?
Sol-Gel SLGL stock price today per share is 0.47 USD.
How to purchase Sol-Gel stock?
You can buy SLGL shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Sol-Gel?
The stock symbol or ticker of Sol-Gel is SLGL.
Which industry does the Sol-Gel company belong to?
The Sol-Gel industry is Biotechnology.
How many shares does Sol-Gel have in circulation?
The max supply of Sol-Gel shares is 27.86M.
What is Sol-Gel Price to Earnings Ratio (PE Ratio)?
Sol-Gel PE Ratio is now.
What was Sol-Gel earnings per share over the trailing 12 months (TTM)?
Sol-Gel EPS is -0.34 USD over the trailing 12 months.
Which sector does the Sol-Gel company belong to?
The Sol-Gel sector is Healthcare.
Sol-Gel SLGL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
| NASDAQ Global Market Composite NQGM | 1647.83 USD — |
-5.17
|
— — | 1610.28 USD — | 1681.06 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
- {{ link.label }} {{link}}